Gilead Sciences and Merck have signed an agreement to assess the efficacy of Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembrolizumab) to treat patients with metastatic triple-negative breast cancer (TNBC).
Biotech company Immunai has raised $215m in Series B funding round to accelerate the development of its immune-first drug actuary platform.
Takeda Pharmaceutical has exercised its option to acquire GammaDelta Therapeutics to accelerate development of allogeneic γδT cell therapies to address solid tumours.
Teva Pharmaceutical has partnered with Modag for the development and licensing of the latter's drug candidates, anle138b and sery433, for neurodegenerative disease.
Vertex Pharmaceuticals has collaborated with Mammoth Biosciences to develop in vivo gene-editing therapies for two genetic diseases.
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has started a rolling review of molnupiravir (MK-4482 and EIDD-2801), an investigational oral antiviral medicine, to treat adult patients with Covid-19.
Clinical-stage biotechnology firm Atreca has signed a licensing agreement with the Bill & Melinda Gates Medical Research Institute (Gates MRI) for the development of a monoclonal antibody to prevent malaria.
Amgen has completed its previously announced acquisition of a clinical-stage biotechnology firm, Teneobio in a deal worth up to $2.5bn.
Silence Therapeutics has announced collaboration with Hansoh Pharmaceutical to develop new therapeutics using Silence’s mRNAi GOLD platform.
Exelixis has signed an exclusive collaboration and license agreement with STORM Therapeutics to discover and develop inhibitors of novel RNA modifying enzymes.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.